Home>>Rituximab (Anti-Human CD20 type I, Chimeric Antibody)
Rituximab (Anti-Human CD20 type I, Chimeric Antibody) 目录号 GC34209


规格 价格 库存 购买数量

Customer Review

Based on customer reviews.

电话:400-920-5774 Email: sales@glpbio.cn

Sample solution is provided at 25 µL, 10mM.


Cell Experiment

Cell lines Two CD20-positive follicular lymphoma cell lines (DOHH-2, WSU-NHL) and one CD20-positive Burkitt's lymphoma cell line (Raji)
Preparation method Samples of 1×10^6 cells/mL medium are incubated with rituximab and the various cytotoxic drugs for 24 and 48 hours.
Concentrations 10 µg/mL
Incubation time 24 and 48 hours

Animal Experiment

Animal models SCID mice
Formulation Saline
Dosages 200 μg
Administration i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

Species  Mouse       Rat     Rabbit      Guinea pig         Hamster         Dog      
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2)                               0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20

Animal A (mg/kg) = Animal B (mg/kg) multiplied by      Animal B Km
                                                                                Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Kmfactor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg

Rituximab (Anti-Human CD20 type I, Chimeric Antibody) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Rituximab (Anti-Human CD20 type I, Chimeric Antibody) Molarity Calculator



Chemical Properties

Cas No. 174722-31-7 SDF Download SDF
别名 IDEC-C2B8
化学名 N/A
Canonical SMILES [Rituximab]
分子式 C6416H9874N1688O1987S44 分子量 144544.44
溶解度 储存条件 Store at -30°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request


Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.

Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells[2].

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3].

[1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50. [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54. [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.